Merck & Co. announced Tuesday that it has completed its acquisition of San Diego-based NovaCardia. The deal, which was worth $366.4M in stock, adds NovaCardia's treatments for acute heart failure to Merck's pipeline. The deal was announced in July. NovaCardia was venture backed by Domain Associates, Forward Ventures, Montreux Equity Partners, Versant Ventures, Skyline Ventures, and InterWest Partners.